Note: Italicized page locators refer to exhibits.

Absolute income hypothesis, 16, 16–17, 29
AC. See Average cost
ACA. See Affordable Care Act
Activities of daily living, 37
Actuarially fair premium: loading factor and, 169; total wealth, expected wealth, and, 168
Actuarially fair price: calculating, 161; definition of, 159
Adverse selection, 166; definition of, 162; discouraging, methods for, 162; health insurance and, 92
Advertising: oligopoly market and, 118
Affordable Care Act, 14, 121, 189; Cadillac tax and, 5; equitable access and, 124–25; individual mandate and, 4; insurance industry and, 165–66; insurance mandate of, opting out of, 159; Medicaid eligibility under, 26; mitigation of adverse selection and, 93; preexisting conditions and, 165, 166; preventive health services and, 40, 189–90; states and Medicaid expansion under, 46
Age: demand and, 92, 94
Agency for Healthcare Research and Quality: Medical Expenditure Panel Survey, 178
Alcohol consumption: elasticity of health and, 49, 50, 53
Allocative efficiency: trade-off between technical efficiency and, 82
American Community Survey, 17
American Medical Association, 140
Animal testing, 123
Anthropogenic, definition of, 42
Antimicrobial drugs, 38, 39
Arc (midpoint) elasticity, 106
Asymmetric information, 120–21
ATC. See Average total cost
Atlantic, The, 5
Auster, R., 50, 51
AVC. See Average variable cost
Average cost: quality and demand increases for monopolistically competitive physician and, 154, 154
Average fixed cost: calculation example, 65, 65; short-run cost curve, 78
Average product: definition of, 59; of labor, marginal product and, 59, 59
Average total cost: short-run cost curve, 77, 78; in short-run costs of production, 66
Average variable cost: short-run cost curve, 77, 78

Backward-bending supply curve of labor: definition of, 147; physician labor supply and, 147–48, 148
Balloon angioplasty, 62
Barriers to entry, healthcare market and, 122
Biological makeup: as health input, 42–43, 47
Bonuses, 143
Brand loyalty: monopolistic competition and, 119
Brand-name drugs, 123
Budget constraints, 97–101; indifference and demand curves linked to, 100–101, 101; optimal amounts of services to purchase, 99; price changes and, 100–101; rotation, as result of price increase, 100; sample, 98–99, 99; utility maximized to, 7, 8, 94
Bureau of Labor Statistics, 177
Buyers: healthcare, 88; in market, 87; monopolistic competition and, 119; monopsony structure and, 122; perfect competition and, 113; rational decisions and, 88
Cadillac tax, 5
Capitation, 142, 147
Catastrophic care, 161
CEA. See Cost-effectiveness analysis
Centers for Medicare & Medicaid Services, 46
Certificate of need, 122, 140; definition of, 122; laws, 122
CHAMPVA. See Civilian Health and Medical Program of the Department of Veterans Affairs
Chance node, in decision tree, 183
Charge, 177
Charity care, 141
Children's Health Insurance Program (CHIP), 14, 45, 46, 161
Cigarette smoking: elasticity of health and, 49, 50, 53
Civilian Health and Medical Program of the Department of Veterans Affairs, 46, 47
Clinical health outcomes: in cost-effectiveness analysis, 179
Clinical trials: stages in, 123
CMS. See Centers for Medicare & Medicaid Services
Coinsurance: definition of, 161; demand and various levels of, 106; moral hazard effects and, 164, 166
Coinsurance rates: demand curve and, 105, 105; pharmaceutical demand and, 108; utilization of physician services and, studies on, 106–7
Community wealth theory, 22
Competition: in insurance market, 165; measuring in insurance market, 170–71; monopolistic, 132, 134
Competitive markets: deviation from, 120–23
Complementary goods and services, 96; definition of, 90; demand and decrease in price of, 104
CON. See Certificate of need
Constant returns to scale, 81–82
Consumer loyalty: monopolistic competition and, 119
Consumer perspective, 179
Consumer price index, 177
Consumers, 3; definition of, 6; health economics assumptions about, 6–7
Consumer surplus: definition of, 130
Copayments: cost consciousness and, 161; demand and, 104–5
Cost–benefit analysis, 175
Cost–effectiveness analysis, 173–91; clinical health outcomes and, 179; cost component of, tasks within, 176–78, 181; definition of, 174, 181; health-related quality of life and, 180; incremental, tasks and components in, 176–78; interpreting results of, 180, 180–81; limitations of, 174, 190; matrix for comparing alternative interventions, 175; Oregon Medicaid program and use of, 190; perspective and, 178–79; policy decisions and use of, 189–90; probabilities and, 189, 190; quality-adjusted life year and, 179–80; scenarios in, 175; sensitivity analyses and, 189; target population and, 176
Cost-effectiveness analysis, flu vaccine, 182–89, 188; complete decision tree with costs and probabilities for flu vaccine, 184; costs of flu vaccine, 182; decision tree for supportive care vs. flu vaccine, 183; flu vaccine (lower arm of decision tree), 185–86; incremental cost-effectiveness ratio in, 186, 188–89; person-years for unvaccinated cohort, 187; person-years for vaccinated cohort, 187; person-years in, 186; quality adjusted life expectancy in, 187–88, 188; quality-adjusted life year in, 188, 188; supportive care (upper arm of decision tree), 183, 185; unvaccinated group, 186; vaccinated group, 186
Cost-minimization analysis, 175
Cost of health production, 73–80; isocost, 73, 74; isoquant, 73, 74; isoquants and no input substitution, 74; isoquants and perfect input substitution, 74–75; marginal cost, average total cost, and average variable cost, 77–79; short-run costs, 75–77
Cost(s): average, 154, 154; average fixed, 65, 65, 66, 78; average total, 66, 77, 78; average variable, 77, 78; economic, 65; fixed, 64; long-run, 65, 68; marginal, 66, 152, 152, 153, 154, 154; monopolistic competition and, 119; opportunity, 65; production and, 64–66; relationship between marginal product and, 77; short-run, 65, 66, 66; time, calculating, 177–78; total, 60, 64; total fixed, 65, 65; typical, for health-related goods and services, 158; variable, 64
Cost-to-charge ratio, 177, 178
CPI. See Consumer price index
Darsky, B. J., 108
Deadweight social loss, 131, 131
Decile: definition of, 24
Decision node, in decision tree, 183
Decision tree: in cost-effectiveness analysis of flu vaccine, 182–83, 183, 184, 185; symbols in, 183
Decreasing returns to scale, 82
Deductibles: definition of, 161; moral hazard effects and, 164, 166
Demand: age and, 92, 94; copayment and effect on, 104–5; decrease in price of substitute service and effect on, 89, 89; definition of, 86; education and, 91, 94; factors affecting, 2; for healthcare, 85–109; for health insurance, 161; for health insurance, factors affecting, 163–65; health status and, 91, 94; income and, 90–91, 94; inelastic, 106; insurance and, 92–93, 94; law of, 88; pharmaceutical, 108; price and, 88–90, 94; price elasticity of services and, 108, 109; quality of care and, 91, 94; supplier-induced, 145–46; tastes and preferences and, 92, 94; time and, 90, 94; understanding, importance of, 87.
See also Elasticity of demand
Demand curve(s): change in price of substitutes and complements and, 103, 104; indifference curves linked to, 101; of monopolistically competitive structure, 132, 132; nerve compression treatment, price insensitivity, and, 133; price change and movement along, 101, 102, 109; shifts in, 102–3; with and without health insurance, 105
Demand–price relationship, 86–87, 87
Demand uncertainty: oligopoly market and, 118
Deprivation: definition of, 25
Deprivation hypothesis, 16, 25–26
Diagnosis-related group, 178
Diminishing returns: in production, reasons for, 59–60
Discount rate: cost-effectiveness analysis and, 177
Diseconomies of scale, 81
Disutility, 90
Diversification: reimbursement rates and, 140
DRG. See Diagnosis-related group
Duopoly, 113, 114, 115, 117
Econometrics, 3
Economic analysis: health policy linked to, 4–5, 6
Economic costs, 65
Economic relationships, 3–4
Economics: in everyday life, 2
 Economies of scale, 67–68, 80
Economies of scope, 68
Economist: definition of, 2, 6
Economist, The, 5
Education: demand and, 91; as health input, 43–44; health–wealth relationship and, 12
Efficiency: goods and services and, 124–25
Elasticity: midpoint, 106; point, 106
Elasticity of demand, 105–6, 134; price, monopoly structure, and, 132; private insurers and, 161
Elasticity of health: definition of, 49, 53; expenditure, research on, 52; interpreting elasticity results, 50
Elasticity of substitution, 71–73, 82; calculating, 72; definition of, 72; evaluated at the mean, 73; studies on, 72
Elective procedures: health insurance and, 93
Emergency departments, 124
Emergency Medical Treatment and Active Labor Act, 117
Empirical analysis: health–wealth relationship and, 21
Employers: health insurance obtained through, 164
EMTALA. See Emergency Medical Treatment and Active Labor Act
End-of-life care: small area variation and, 144
Environment: as health input, 41–42, 47; health–wealth relationship and, 12
Equilibrium output: perfect competition and, 126
Equilibrium price, 88; definition of, 7; perfect competition and, 126
Equilibrium quantity, 7, 88
Equity: goods and services and, 124–25
Ettner, Susan, 21
Exercise, 41
Expected utility, 171; definition of, 169; risk and, 168–69
Expected wealth: definition of, 168
Expenditure elasticity of health: research on, 52
Externalities, 130–31; negative, 122; perfect competition and lack of, 115; positive, 122
Fairman, K. A., 108
Federal poverty level: critical level of income and, 25–26
Federation of State Medical Boards, 87
Fee-for-service, 142; economic incentives and, 143, 147; supplier-induced demand and, 145; supplier-induced demand theory and, 149
Financial incentives: capitation, 142, 143; copayments, deductibles, and, 161; fee-for-service method, 142, 143, 143, 147; salaries, 143
Fixed costs, 64; profit level, shut-down point, and, 80
Flu vaccine: complete decision tree with costs and probabilities for, 184; cost-effective analysis example, 182–83, 185–89; costs of, 182; decision tree for supportive care vs., 183; person-years for unvaccinated cohort, 187; person-years for vaccinated group, 187; quality-adjusted life expectancy (unvaccinated group), 188; quality-adjusted life expectancy (vaccinated group), 188
Food and Drug Administration, 87
For-profit businesses: profit distribution to shareholders, 141; profits and, 64; taxes and, 141
Freedom of entry and exit: perfect competition and, 113
Free market: definition of, 87
Fuchs, V. R., 50
Garner, D. D., 108
GDP. See Gross domestic product
Gender: biological and genetic health determinants and, 42
Generic drug manufacturers: marginal cost of production and, 124
Generic drugs, 123
Genetic factors: as health input, 42–43, 47
Gini coefficient: measuring inequality of wealth and, 23, 24
GNP. See Gross national product
Goldman, D. P., 108
Goods and services, health-related: budget constraints and, 97–101; complementary, 90, 96–97; efficiency, equity, and, 124; insurance and demand for,
206 Index

92; law of demand and, 88; preventive, health status and demand for, 91; related, price of, 89; supplier-induced demand and, 145; utility and, 6–7

Government: monopolies and, 116

Government insurance programs, 161; Children’s Health Insurance Program, 45, 46; Civilian Health and Medical Program of the Department of Veterans Affairs, 46, 47; as health input, 45–47; Indian Health Service, 46, 47; Medicaid, 45, 46; Medicare, 45, 46; TRICARE, 45, 47

Gradient: definition of, 15

Great Recession: effects of, economic analysis, 5

Greenlick, M. R., 108

Gross domestic product: health improvements, lowered income inequality, and, 29; medical expenditures as percentage of, 36; per capita, health indicators and, 27; strength of economy and, 28

Gross national product: nonlinear relationship between life expectancy and, 28–29, 29; strength of economy and, 29

Group insurance: supply and, 165

Group practice: benefits of working in, 138, 146; economies of scope and scale in, 138; market power and, 138; physicians’ transition from solo practice to, 137–38

Hadley, J., 51

Happiness: utility and, 6, 94

Health: elasticity of, 49; subjective measures of, 37–38. See also Production of health

Health Affairs, 5

Healthcare: buyers and sellers of, 88; insurance and reduced out-of-pocket costs for, 92; market power in, 139.

See also Demand for healthcare; Goods and services, health-related

Healthcare decisions: insured individuals and, 164

Healthcare expenditures: continuous rise in, 36

Healthcare market: barriers to entry, 122; supply-and-demand model applied to, 128, 128–30, 129

Healthcare providers: technology adoption and, 63

Health economists: questions formulated by, 3

Health expenditures: elasticity of health and, 49, 50, 53

Health inputs, 36, 38–47; biological makeup, 42–43, 47; education, 43–44, 47; environment, 41–42, 47; government programs, 45–47; housing, 44–45, 47; income, 43; income–health relationship, 43; law of diminishing returns and, 39–40; lifestyle, 40–41; medical-based, 38; nonlinear relationship between health status and, 48, 48, 52

Health insurance: adverse selection and, 92, 162; demand and, 92–93, 94, 161; demand curves with and without, 105; factors affecting demand for, 163–65; financing structure, 161; moral hazard and, 93, 164; predictability factor and, 158; premiums, 40; price sensitivity and, 104, 105, 105; RAND Health Insurance Experiment, 52, 107, 108, 109; unequal distribution of income
and unequal access to, 23; utility and purchase of, 168–69; wealth and access to, 11, 11, 43, 47
Health insurance companies, 88
Health insurance industry: oligopoly structure and, 118, 125
Health insurance premiums: Affordable Care Act, adverse selection, and, 93; definition of, 160; risk pooling and, 159–60
Health literacy, 12
Health maintenance organizations, 107
Health output, 57–58
Health policy: economic analysis linked to, 4–5, 6
Health production. See Cost of health production; Production of health
Health production function, definition of, 48
Health programs: quality-adjusted life years and, 38
Health-related quality of life, 180; in cost-effectiveness analysis, flu vaccine, 187, 188, 190
Health state: contextualizing, 179–80
Health status: bidirectional relationship between income level and, 12, 13, 13; community wealth theory and, 22; concave relationship between income level and, 20, 20–21; demand and, 91, 94; elasticity of health and, 49; health production function and, 48; investing in education and, 44; linear relationship between income level and, 13, 14; measuring, 37–38, 47; nonlinear relationship between health inputs and, 48, 48, 52; nonlinear relationship between income level and, 15, 15; position within community and, 26; shifts in demand curve and, 102, 103, 103
Health–wealth relationship: dynamics within, 11–13; graphing, 13; international studies on, 27–29. See also Income–health theories
Healthy People 2020, 42
Herd immunity, 122, 130
Herfindahl-Hirschman Index (HHI): calculating, 170–71
HIV status: biological and genetic health determinants and, 42
HMOs. See Health maintenance organizations
Homogeneous products: perfect competition and, 114
Hospitals: cost-to-charge ratios, 178; profit level and shut-down point for, 79–80
Housing: as health input, 44–45
HRQL. See Health-related quality of life
Hypotheses: drawing firm conclusions about, 25
ICER. See Incremental cost-effectiveness ratio
Immunization: herd immunity and, 122, 130
Incentives. See Financial incentives
Incidence: definition of, 37
Income: demand and, 90–91, 94; demand for health insurance and, 163; as health input, 43; of physicians, 147; shifts in demand curve and, 103
Income distribution and health, at the national level, 18
Income effect, 89; physician labor supply and, 147–48, 154
Income–health relationship, 43
Income–health theories, 15–18, 16; absolute income hypothesis, 16, 16–17, 20–22; deprivation hypothesis, 16, 25–26; income inequality hypothesis, 16, 22–25; relative income hypothesis, 16, 17–18, 22; relative position (or rank) hypothesis, 16, 26–27
Income inequality: results of studies on, 25
Income inequality hypothesis, 16, 22–25; definition of, 23; studies not supportive of, 25; studies supportive of, 25
Income level: bidirectional relationship between health status and, 12, 13, 13; concave relationship between health status and, 20, 20–21; linear relationship between health status and, 13, 14; nonlinear relationship between health status and, 15, 15
Increasing returns to scale, 81
Incremental cost-effectiveness ratio, 176, 180, 181; in cost-effectiveness analysis, flu vaccine, 186, 188–89; denominator in, 186, 190; numerator in, 186, 190
Indifference curve(s): for complements, 96, 96–97; definition of, 94; linking to budget constraints, 100; linking to demand curves, 101; negative slope of, 95; as straight lines or bent toward the origin, 96; for substitutes, 97, 97; three, indifference map with, 95; utility constant along, 94–95
Indifference map: definition of, 95; with three indifference curves, 95
Inelastic demand, 106
Inequality of wealth: Gini coefficient and, 23, 24; Lorenz curve and, 24, 24; measuring, 23–24
Infant mortality rate: definition of, 37; gross domestic product per capita and, 27
Information: asymmetric, 120–21
Inherited conditions, 42–43
Inputs: technology and productivity of, 61
Input substitution, 58
Inquiry, 5
Insurance. See Health insurance
Insurance companies: reimbursement rates, physicians’ market power, and, 139
Insurance market, 157–72; Affordable Care Act and, 165–66; competition in, 165; insurance process, 160–62; loading factor and, 169; measuring competition in, 170–71; risk and uncertainty, 158–60; risk aversion and utility and, 167–69; risk lovers and, 169–70
Insurance policies: purpose of, 158–60, 166
Interdependence, oligopoly market and, 118
Internet: medical information and, 137
Interventions: comparing economic worth of, 175, 175; incremental cost-effectiveness ratio and, 176, 180, 181
Isocost: definition of, 73
Isocost–isoquant diagram, 74
Isoquant: definition of, 73; no input substitution and, 74, 75; perfect input substitution and, 74–75, 75
Jensen, G. A., 72
Joyce, G. F., 108
Kindig, D., 72
Labor: marginal product of, 72, 72; substitutability of, 72, 73. See also Physician labor supply
Latex gloves: market shortage caused by increased demand for, 128, 128
Law of demand: definition of, 88
Law of diminishing marginal productivity, 71
Law of diminishing marginal utility, 96
Law of diminishing returns, 39–40, 58
Lead-based paint, 45
Leveson, I., 50, 51
Libby, D., 72
Life expectancy: nonlinear relationship between gross national product and, 28–29, 29; in United States, 37
Lifestyle: adverse selection and, 92; demand and, 92, 94; as health input, 40–41, 47; health–wealth relationship and, 12; production of health and, 51, 53
Loading factor, 161, 169
Long-run average total cost (LRAC) curve, 80, 81
Long-run costs: definition of, 65; of production, 68
Lorenz curve: measuring inequality of wealth and, 23, 24, 24
Loss potential: magnitude of demand for health insurance and, 163
Managed care: technology and, 63
Marginal cost, 66; declining demand for monopolistically competitive physician and, 153, 153; monopolistically competitive physician and, 152, 153; price discrimination and, 151, 152; quality and demand increases for monopolistically competitive physician, 154, 154; short-run cost curve, 78; short-run costs of production, 66
Marginal cost curves: marginal product and, 79, 79
Marginal private benefit, 130, 130
Marginal product, 39, 47; average product of labor and, 59, 59; diminishing returns and, 58–60; of health inputs, diminishing, 49; health program funding and, 49; of labor, 72, 72; marginal cost curves and, 79, 79; profit and, 60–61, 61; relationship between costs and, 77
Marginal productivity: short-run marginal cost and, 77
Marginal rate of substitution, 99, 109
Marginal revenue, 126; declining demand for monopolistically competitive physician and, 153, 153; monopolistically competitive physician and, 152, 153; price discrimination and, 151, 152; quality and demand increases for monopolistically competitive physician and, 154, 154
Marginal social benefit, 131, 131
Marginal utility: graphical representation of, 167, 168
Marginal utility of income: definition of, 167; lack of uniformity in, 167
Market: definition of, 87; free, 87
Market concentration: definition of, 141
Market power: definition of, 138; in healthcare, 139
Market power, of physicians: forms of, 138–41; group practice and, 138; higher reimbursement rates and, 139; lower price and, 139–40; market concentration and, 141; regulations and, 140; tax advantage and, 141
Market structure(s): categorizing, 113; cost of differentiation, 119–20; duopoly, 114, 115, 117; monopolistic competition, 114, 115, 119; monopoly, 114, 115, 116–17; monopsony, 114, 122–23; oligopoly, 114, 115, 117–18; perfect competition, 113–14, 114; in pharmaceutical industry, 123–24, 125; types of, 114
Market supply: definition of, 87
MC. See Marginal cost
Medicaid, 6, 14, 45, 46, 137, 144; deprivation hypothesis and, 26; financing mechanism for, 161; introduction of, 129; prospective payments, 64; reimbursement rates, 140
Medical-based inputs, 38, 47
Medical care: quality and rising price of, 152–54
Medical Expenditure Panel Survey (Agency for Healthcare Research and Quality), 178
Medical expenditures: continuous rise in, 36; study on production of health and, 51
Medical technology, 38, 39; definition of, 61; rising physician prices and, 152
Medicare, 6, 45, 46, 144; diagnosis-related groups, cost-to-charge ratios, and, 178; financing mechanism for, 161; introduction of, 129; prospective payments, 64; reimbursement rates, 140
Medicare Payment Advisory Commission (MedPAC), 4
Microeconomics: fundamental assumptions in, 6–8; health economics rooted in, 6
Midpoint elasticity, 49–50, 106
Milbank Quarterly, 5
Monopolistically competitive market structure: physicians and, 142, 147
Monopolistically competitive physicians: decline in demand and, 153, 153; perfectly competitive price and, 152, 153; quality and demand increases for, 154, 154
Monopolistically competitive structure, 132, 134; long-run monopolistically competitive firm, 133; short-run, monopoly structure and, 132
Monopolistic competition, 114, 115; characteristics of, 119; definition of, 115
Monopoly, 113, 114, 115, 125; pharmaceutical market as example of, 124; reasons for, 116; structure of, 132, 132
Monopsony, 114, 122–23
Moral hazard: health insurance and, 93; insurance market and, 164, 166
Morbidity: definition of, 37
Morgenstern, Oskar, 167
Morrisey, M. A., 72
Mortality: relative income and, 23; results of studies on, 25; studies on effect of income on, 21; Whitehall Study of, 27
Motheral, B., 108
MR. See Marginal revenue
MRS. See Marginal rate of substitution
Multispecialty groups: benefits of, 138; economies of scope and scale in, 138
Narrow distribution of income: health status and, 18
National Health Service (United Kingdom): excess demand in zero copayment market and, 128, 129, 130
Negative externality, 115, 122
Neighborhood condition: health outcomes and, 45
Nerve compression treatment: potential, price insensitivity and demand curve for, 133
Nevada: research on death rates in, 50
New drug approval: costs related to, 123
New York City: median household income in, 17
New York Times, 5
No input substitution: isoquants and, 74, 75
Non-health-related subjects: examples of, 4
Normal good, 91
Not-for-profit businesses: reinvestment of profits and, 7, 64, 141; tax advantages for, 141
Nurses: substitutability of labor and, 72, 73
Obesity, 43, 44
Occupational rank and health: Whitehall Study findings on, 27
Oligopoly, 113, 114, 115, 117–18; characteristics of, 118; definition of, 115, 118; pharmaceutical market as example of, 124
Opportunity cost, 65
Oregon: cost-effectiveness analysis and Medicaid program in, 190
Out-of-pocket healthcare costs: health insurance, predictability factor, and, 158; insurance and reduction in, 92; moral hazard and, 93
Output: under perfect competition, 125–27
Oversaturation: certificate of need and, 140
Patent: definition of, 124
Payers, 3; definition of, 6; health economics assumptions about, 7–8
Payment cross-subsidization, 144
Payment methods, physician, 142–44; capitation, 142, 143, 147; cross-subsidization, 144; fee-for-service, 142, 143, 147, 147; salary, 143
Perfect competition, 114; deviation from, 120–23; firm taking a price from the industry, 126, 126; impact of profits on market activity, 127, 127; nonexistence of externalities in, 122; operating conditions in, 113–14; short-run price and output under, 125–27
Perfect complements: definition of, 97; indifference curves for, 96
Perfect input substitution: isoquants and, 74–75, 75
Perfect knowledge, 114
Perfectly competitive markets: physicians and, 141; pricing mechanism in, 8
Perfect substitutes: indifference curves for, 97
Person-years: cost-effectiveness analysis, flu vaccine, 186, 187
Perspective, 178–79
Pharmaceutical demand, 108
Pharmaceutical industry: market structure in, 123–24, 125
Physician agent, 146
Physician assistants: substitutability of labor and, 72, 73
Physician behavior, 136–56; market power for physicians, 138–41; payment methods, 142–44; physician labor supply, 147–48; physicians as monopolistically competitive, 141–42, 152, 153, 153, 154, 154; rising physician prices, role of quality in, 152–54; small area variation, 144–45; supplier-induced demand, 145–46; supplier-induced demand theory and, 148–51; transition from solo to group practice, 137–38
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physician fees: competitive model and</td>
<td>129</td>
</tr>
<tr>
<td>Physician-induced demand</td>
<td>145</td>
</tr>
<tr>
<td>Physician labor supply: backward-bending supply curve of</td>
<td>147–48</td>
</tr>
<tr>
<td>labor and</td>
<td></td>
</tr>
<tr>
<td>Physician prices: rising, role of quality in</td>
<td>152–54</td>
</tr>
<tr>
<td>Physicians: MedPAC and pricing differential for</td>
<td>4–5</td>
</tr>
<tr>
<td>as monopolistically competitive</td>
<td>141–42</td>
</tr>
<tr>
<td>147, 152, 153, 154, 153, 154</td>
<td></td>
</tr>
<tr>
<td>Physician-to-population ratio, 149–50, 154; increase in</td>
<td>149, 150</td>
</tr>
<tr>
<td>labor supply and</td>
<td></td>
</tr>
<tr>
<td>Point elasticity</td>
<td>106</td>
</tr>
<tr>
<td>Policymakers: understanding demand and</td>
<td>87</td>
</tr>
<tr>
<td>Policymaking process: cost-effectiveness analysis</td>
<td>189–90</td>
</tr>
<tr>
<td>economic analysis and</td>
<td>4–5</td>
</tr>
<tr>
<td>Pollution: health and impact of</td>
<td>42</td>
</tr>
<tr>
<td>Population-level measures</td>
<td>37</td>
</tr>
<tr>
<td>Position: health status and</td>
<td>26</td>
</tr>
<tr>
<td>Positive externality</td>
<td>115, 122</td>
</tr>
<tr>
<td>PPF. See Production possibility frontier</td>
<td></td>
</tr>
<tr>
<td>Preexisting conditions: Affordable Care Act and,</td>
<td>165, 166</td>
</tr>
<tr>
<td>Preferences. See Tastes and preferences</td>
<td></td>
</tr>
<tr>
<td>Preference scores</td>
<td>180</td>
</tr>
<tr>
<td>Premiums. See Health insurance premiums</td>
<td></td>
</tr>
<tr>
<td>Prescription drugs: brand-name, demand and,</td>
<td>108, 123</td>
</tr>
<tr>
<td>generic, 123; patent protection for, 124</td>
<td></td>
</tr>
<tr>
<td>Present value: cost-effectiveness analysis and, 177</td>
<td>62</td>
</tr>
<tr>
<td>technology adoption and</td>
<td></td>
</tr>
<tr>
<td>Preventive care: Affordable Care Act and, 40, 189–90;</td>
<td></td>
</tr>
<tr>
<td>health status and demand for, 91</td>
<td></td>
</tr>
<tr>
<td>Price: budget constraint and changes in, 100–101;</td>
<td></td>
</tr>
<tr>
<td>demand and, 88–90, 94; demand for health insurance and,</td>
<td></td>
</tr>
<tr>
<td>163; duopoly structure and, 117; health-related goods</td>
<td></td>
</tr>
<tr>
<td>and services and, 86, 89–90; monopoly structure and,</td>
<td></td>
</tr>
<tr>
<td>116; movement along demand curves and change in, 101, 102</td>
<td></td>
</tr>
<tr>
<td>109; oligopoly market and, 118; in perfectly competitive</td>
<td></td>
</tr>
<tr>
<td>market, 8</td>
<td></td>
</tr>
<tr>
<td>Price discrimination: supplier-induced demand theory and</td>
<td>150–51</td>
</tr>
<tr>
<td>Price elasticity: definition of, 105; of demand, 105–6, 109</td>
<td></td>
</tr>
<tr>
<td>Price negotiations: private health insurance companies</td>
<td>64</td>
</tr>
<tr>
<td>Price of complement: shifts in demand curve and, 103</td>
<td></td>
</tr>
<tr>
<td>Price of substitute: shifts in demand curve and, 102–3</td>
<td></td>
</tr>
<tr>
<td>Price sensitivity: demand for healthcare and, 104;</td>
<td></td>
</tr>
<tr>
<td>demand for healthcare and, literature review of, 106–8;</td>
<td></td>
</tr>
<tr>
<td>monopoly structure and, 132; physician-segmented practices</td>
<td></td>
</tr>
<tr>
<td>and, 151</td>
<td></td>
</tr>
<tr>
<td>Price setters: monopolistic competition and, 119</td>
<td></td>
</tr>
<tr>
<td>Price setting: physicians’ market power and, 139–40</td>
<td></td>
</tr>
<tr>
<td>Price takers: perfect competition and, 114</td>
<td></td>
</tr>
<tr>
<td>Principal–agent relationship</td>
<td>146</td>
</tr>
<tr>
<td>Private health insurance companies: price negotiations</td>
<td>64</td>
</tr>
<tr>
<td>Private perspective, 178, 179</td>
<td></td>
</tr>
<tr>
<td>Probabilities: cost-effectiveness analysis and, 189, 190</td>
<td></td>
</tr>
<tr>
<td>Probability of healthcare event: demand for health</td>
<td></td>
</tr>
<tr>
<td>insurance and, 163</td>
<td></td>
</tr>
</tbody>
</table>
Producers, 3; definition of, 6; health economics assumptions about, 7
Producer surplus: definition of, 130
Product differentiation, 121; oligopoly market and, 118
Production: cost and, 64–66; definition of, 71
Production costs: monopolistic competition and, 119
Production function: definition of, 48, 71; elasticity of substitution and, 71–73
Production of health, 35–53; factors influencing, 39; health inputs, 36, 38–47; input–output relationship and, 57–58; literature on, review of, 49–52; measuring health status, 37–38; seminal studies, 50–52
“Production of Health: An Exploratory Study” (Auster, Leveson, and Sarachek), 50
Production possibility frontier, 69–71; definition of, 69; sample, 69
Profit(s): bonuses and, 143; cost curves and, 80; definition of, 60; determining, in the short run, 127; impact of, on market activity, 127, 127; marginal product and, 60–61, 61; monopolistic competition and, 119; shut-down point and level of, 79–80; taxes and, 141
Prospective payments, 64
Protease inhibitors, 62
Provider substitution: unintended consequences of, 98
Public health, 38, 39
Public policy: informing, with stable results, 25, 29
QALE. See Quality-adjusted life expectancy
Quality: rising physician prices and, 152–54
Quality-adjusted life expectancy: in cost-effectiveness analysis, flu vaccine, 187–88, 188
Quality-adjusted life year, 37, 38; in cost-effectiveness analysis, flu vaccine, 188, 188; cost-effectiveness analysis and, 179–80, 181; effectiveness measured in, 176
Quality of care: demand and, 91, 94
Quantity demand: inverse relationship between price and, 88
RAND Health Insurance Experiment, 52, 107, 108, 109
Rational decisions: marketplace dynamic and, 88
Real income, 88
Regulations: physicians’ market power and, 140
Reimbursement rates: diversification and, 140; physicians’ market power and, 139
Relative income hypothesis, 16, 17–18; definition of, 17; individual health and, 22
Relative position (or rank) hypothesis, 16, 26–27; definition of, 26; mathematical explanation of, 27; research studies on, 27
Relative price, 88
Residents: substitutability of labor and, 72, 73
Returns to scale: constant, 81–82; decreasing, 82; increasing, 81
Revenue formula, 89
Revenue levels: monitoring, 141
Riportella-Muller, R., 72
Risk: estimating, 162; expected utility and, 168–69; health insurance market, uncertainty, and, 158–60
Risk averse: definition of, 158
Risk aversion, 171; demand for health insurance and, 163, 166; utility and, 167–69
Risk lovers: health insurance and, 159; marginal utility of wealth for, 170
Risk-neutral individuals: health insurance and, 159
Risk pools, 159–60; adverse selection and, 162; low- and high-risk groups in, 160
Risk premium (loading factor), 169
Salaries: elasticity-of-substitution example, 71; physician payment methods and, 143
Sarachek, D., 50, 51
SATC curve. See Short-run average total cost curve
Satisfaction: utility and, 6, 94
SAV. See Small area variation
Scale: in economics, 67
Scitovsky, A. A., 106, 107
Sedentary lifestyle: illness and, 43
Self-assessed health: empirical analysis of, 21
Self-insurance, 163
Sellers: healthcare, 88; in market, 87; monopolistic competition and, 119; rational decisions and, 88
Sensitivity analyses, 189
Shareholders: profit distribution to, 141
Short-run average total cost curve, 80, 80
Short-run cost, 65, 75–77; curves, 77, 78; of production, 66, 66
Short-run marginal cost: curve, 80; marginal productivity inversely related to, 77
Short-run price: under perfect competition, 125–27
Short-run total cost: curve, 76; increasing hospital services and, 76
Shut-down point: profit level and, 79–80
Sleep, 41
Small area variation, 144–45
SMC. See Short-run marginal cost
Smith, M. C., 108
Smoking, 41
SNAP. See Supplemental Nutrition Assistance Program
Snyder, N., 106, 107
Social capital: definition of, 41
Social perspective, 179
Solo practice: physicians’ transition to group practice from, 137–38
Stable results, in research studies, 25
States: Affordable Care Act and Medicaid expansion in, 46; highly concentrated insurance markets in, 171
Sticky prices: oligopoly market and, 118
Substitute goods or services: indifference curves for, 97, 97; price, demand, and, 89, 89, 104
Substitution: input, 58; marginal rate of, 99; no input, isoquants and, 74, 75; perfect input, isoquants and, 74–75, 75; unintended consequences of, 98. See also Elasticity of substitution
Substitution effect: definition of, 89; physician labor supply and, 147–48, 154
Supplemental Nutrition Assistance Program, 14
Supplier-induced demand, 145–46, 147; definition of, 145; physician agent and, 146; target income hypothesis and, 146
Supplier-induced demand theory, 148–51; physician-to-population ratio, 149–50; price discrimination, 150–51, 152
Supply: group insurance and, 165
Supply-and-demand model, 134; applying to healthcare markets, 128, 128–30, 129; externalities and, 130–31
Supply oversaturation: certificate of need and, 140

Target income hypothesis, 146
Target population: cost-effectiveness analysis and, 176
Tastes and preferences: demand and, 92, 94; shifts in demand curve and, 103
Taxes: demand for health insurance and, 164; physicians’ market power and, 141; public or government insurers and, 161
Technical efficiency: trade-off between allocative efficiency and, 82
Technological change: ripple effects of, examples, 62
Technology: adoption, 62–63; managed care and, 63; production and, 61–63
Terminal node, in decision tree, 183
TFC. See Total fixed cost
Thailand: gross domestic product per capita and infant mortality rate in, 27
Therapeutic class of prescription drugs, 124
Third-party payers, 137
Thornton, J., 51
Time: demand and, 90–91, 94
Time cost, calculating, 177–78
Total cost, 64; definition of, 60; in short-run costs of production, 66
Total fixed cost: calculation example, 65, 65; in short-run costs of production, 66
Total profit formula, 60
Total revenue formula, 60
Total variable cost: in short-run costs of production, 66
Travel time: demand for healthcare and, 90
Treatment options: small area variation and, 144–45
TRICARE, 45, 47
TVC. See Total variable cost
Uncertainty, 121, 169; demand for health insurance and, 163; health insurance market, risk, and, 158–60
Uninsured population, 159
United States: Affordable Care Act, equitable access, and, 124–25; death rates of poor people in, 23; free market in, 87; gross domestic product per capita and infant mortality rate in, 27; income distribution and health in, 18; life expectancy in, 37; median and mean household income in, 19; poverty guidelines for 48 contiguous states and District of Columbia, 26
Unnecessary services: supplier-induced demand and, 145, 147
Unstable results, in research studies, 25
US Preventive Services Task Force, 189
Utah: research on death rates in, 50
Utility: budget constraint and, 7, 8; definition of, 6, 8, 94; expected, 168, 169, 171; maximizing, 89, 167; risk aversion and, 167–69
Utilization: health plan stipulations and, 164; of physician services, coinsurance study on, 106–7
Vaccinations: herd immunity and, 122, 130; societal benefit and social loss and, 131, 131
Variable cost, definition of, 64
Veterans Health Administration (VHA), 46  
Welfare gain, 165  

von Neumann, John, 167  
Welfare loss: insurance coverage  
and, 165  

Wages: backward-bending supply curve of  
labor and, 147–48, 148; monopsony  
structure and, 123  
Whitehall Study, 27  

Waiting time: demand for healthcare and,  
90  
Wide distribution of income: health status  
and, 18  

Washington Post, 5  
Willingness to pay: measuring, difficulty  
in, 86–87  

Wealth: diminishing marginal utility of,  
167, 168; expected, 168; marginal  
utility of, for risk lovers, 170; use of  
term, 11  
Workplace: health–wealth relationship  
and, 12  

Wealth–health relationship: dynamics  
within, 11–13; graphing, 13; interna- 
tional studies on, 27–29. See also  
Income–health theories  
World Bank, 28  
World Health Organization, 28  

Zero copayment: excess demand in mar-
ket with, 128, 129, 130  
Zero economic profits: perfect competi-
tion and, 115